Weight change from 3-year observational data: Findings from the worldwide schizophrenia outpatient health outcomes database

Journal of Clinical Psychiatry

Volumn 73, Issue 6, 2012, Pages

  Bushe, Chris J ^a   Slooff, Cees J ^c,d   Haddad, Peter M ^b   Karagianis, Jamie L ^e  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Psychiatric University Clinic Groningen   (Netherlands)

^d Lilly USA ^*  (United States)

^e MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CLOZAPINE; DEPOT FIRST GENERATION ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG;

ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; OBESITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84863554395     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11m07246     Document Type: Article

References (25)

1. Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol. 2005;19(suppl):16-27. doi:10.17/02698105058378 PubMed (Pubitemid 44567855)
2. Bushe C, Sniadecki J, Bradley AJ, et al. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. J Psychopharmacol. 2010;24(7):1001-1009. doi:10.17/02698108101783 PubMed
3. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11): 1686-1696. PubMed (Pubitemid 29517559)
4. Kahn RS, Fleischhacker WW, Boter H, et al; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097. doi:10.1016/S0140-6736(08)60486-9 PubMed (Pubitemid 351418005)
5. Lieberman JA, Stroup TS, McEvoy JP, et al Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. doi:10.1056/NEJMoa05168 PubMed (Pubitemid 41345943)
6. Hamer S, Haddad PM. Adverse effects of antipsychotics as outcome measures. Br J Psychiatry suppl. 2007;191(suppl 50):s64-s70. doi:10.192/bjp.191.50.s64 PubMed (Pubitemid 47204558)
7. Haro JM, Edgell ET, Jones PB, et al SOHO Study Group. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand. 2003;107(3):222-232. doi:10.1034/j.160-047. 203.064.x PubMed (Pubitemid 36250283)
8. Dossenbach M, Erol A, el Mahfoud Kessaci M, et al; IC-SOHO Study Group. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry. 2004;65(3):312-321. doi:10.408/JCP.v65n0305 PubMed
9. Haro JM, Suarez D, Novick D, et al SOHO Study Group. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol. 2007;17(4):235-244. doi:10.1016/j.euroneuro.206.09.05 PubMed (Pubitemid 46164772)
10. Karagianis J, Novick D, Pecenak J, et al. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract. 2009;63(11):1578-1588. doi:10.1/j.1742-1241.209.02191.x PubMed
11. Fitzmaurice G, Davidian M, Verbeke G, et al, eds. Handbooks of Modern Statistical Methods: Longitudinal Data Analysis. Boca Raton, LA: Chapman & Hall/CRC Press; 2008.
12. Laubender RP, Bender R. Estimating adjusted risk difference (RD) and number needed to treat (NNT) measures in the Cox regression model. Stat Med. 2010;29(7-8):851-859. doi:10.102/sim.3793 PubMed
13. Smith S, Yeomans D, Bushe CJP, et al. A well-being programme in severe mental illness: reducing risk for physical ill-health: a post-programme service evaluation at 2 years. Eur Psychiatry. 2007;22(7):413-418. doi:10.1016/j.eurpsy. 207.07.02 PubMed (Pubitemid 47610815)
14. Bushe CJ, Bradley AJ, Doshi S, et al. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? a systematic review of clinical studies. Int J Clin Pract. 2009;63(12):1743-1761. doi:10.1/j.1742-1241.209.024.x PubMed
15. Holt RIG, Pendlebury J, Wildgust HJ, et al. Intentional weight loss in overweight and obese patients with severe mental illness: 8-year experience of a behavioral treatment program. J Clin Psychiatry. 2010;71(6):800-805. doi:10.408/JCP.09m05627gre PubMed
16. Bushe CJ, McNamara D, Haley C, et al. Weight management in a cohort of Irish inpatients with serious mental illness (SMI) using a modular behavioural programme; a preliminary service evaluation. BMC Psychiatry. 2008;8(1):76. doi:10.186/1471-24X-8-76 PubMed
17. Pendlebury J, Bushe CJ, Wildgust HJ, et al. Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Acta Psychiatr Scand. 2007;115(4):286-294. doi:10.1/j.160-047.206.0906.x PubMed (Pubitemid 46425749)
18. Brecher M, Leong RW, Stening G, et al. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry. 2007;68(4):597-603. doi:10.408/JCP.v68n0416 PubMed (Pubitemid 46663043)
19. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. Schizophr Res. 2008;99(1-3):13-22. doi:10.1016/j.schres.207.10.02 PubMed (Pubitemid 351255577)
20. Millen BA, Campbell GM, Beasley CM. Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials. J Psychopharmacol. 2011;25(5):639-645. doi:10.17/ 0269810370505 PubMed
21. Lambert M, Haro JM, Novick D, et al. Olanzapine vs other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand. 2005;111(3):232-243. doi:10.1/j.160-047.204.0451.x PubMed (Pubitemid 40342192)
22. Novick D, Haro JM, Perrin E, et al. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol. 2009;19(8):542-550. doi:10.1016/j.euroneuro.209.03.03 PubMed
23. Bushe C, Haddad P, Peveler R, et al. The role of lifestyle interventions and weight management in schizophrenia. J Psychopharmacol. 2005;19 (suppl):28-35. doi:10.17/02698105058682 PubMed (Pubitemid 44567856)
24. Kinon BJ, Kaiser CJ, Ahmed S, et al. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol. 2005;25(3):255-258. doi:10.1097/01.jcp.0161501.65890.2 PubMed (Pubitemid 40685790)
25. Addington J, Saeedi H, Addington D. Weight gain in first-episode psychosis over three years. Schizophr Res. 2006;86(1-3):335-336. doi:10.1016/j.schres.206.06.035 PubMed (Pubitemid 44234066)